Management

Claudia Jimenez

Claudia Jimenez

General Director

+ More info
x

Claudia Jimenez

General Director

Claudia has 20 years of experience and a proven record of accomplishment in corporate development, investor relations and communications. She started her career in corporate finance at WestLB AG in Germany, where she managed mergers and acquisition (M&A) projects across various industries. Following the completion of her MBA at Instituto de Empresa in 2005, she joined the biotechnology company TiGenix, taking responsibility for corporate development and leading the company’s partnering efforts that culminated in a deal with Takeda worth up to €380M. Following the company’s Nasdaq IPO, Claudia became responsible for investor relations and corporate communications until the completion of the acquisition of TiGenix by Takeda in 2018.

José Escribano

José Escribano

Founder and CSO

+ More info
x

José Escribano

Founder and CSO

Jose is a specialist in viral infectious diseases and in the development of biotechnology applications of viruses, with more than 120 scientific contributions in international journals and numerous licensed patents. He is on the editorial board of several virology and biotechnology journals. José is a graduate and Ph.D from Complutense University of Madrid in Veterinary Medicine and carried out postdoctoral studies in different institutions of USA. Jose served as Research Professor in a Spanish scientific institution and has over 25 years of experience in science management. As entrepreneur, he is co-founder of ALGENEX and LogicBiology.

Virginia Gonzalez

Virginia Gonzalez

CFO

+ More info
x

Virginia Gonzalez

CFO

Virginia has more than 20 years’ experience in finance. She started her career in the finance department of Decathlon after completing her degree in Business Administration at the University of Oviedo, Spain. She later joined the biotechnology company TiGenix, a dual listed Company (Nasdaq & Euronext ) which was acquired by Takeda 2019. During her 13 years at TiGenx she held different roles of responsibility, including finance director and head of controlling and consolidation. Virginia holds a master in Business Administration from CEF and an Advance Management Program from Instituto de Empresa, Madrid.

Romy Dalton

Romy Dalton

COO

+ More info
x

Romy Dalton

COO

Romy has more than 17 years of experience on Molecular Biology and Virology and eleven scientific publications in peer reviewed journals. She has worked first as a researcher and then as a Project Leader at several Biotech Companies. She joined Algenex more than three years ago in the position of Chief Operations Officer and manages the Comercial Agreements, Human Resources, Patent Portfolio and supervises the scientific projects.

Strategic Advisory Board

Claudia D´Augusta

Claudia D´Augusta

CFO Vectivbio

+ More info
x

Claudia D´Augusta

CFO Vectivbio

Claudia D’Augusta has over 20 years of experience in corporate finance, 14 of which have been in the life sciences sector. She currently serves as CFO of VectviBio a spin off of Therachon (sold to Pfizer in 1H 2019 for a total deal value of 810M USD) a Swiss clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions.

Dr. Damià Tormo

Dr. Damià Tormo

Founder and managing partner of Columbus Venture Partners

+ More info
x

Dr. Damià Tormo

Founder and managing partner of Columbus Venture Partners

Damià has been widely recognized for his capacity to combine a brilliant scientific career with that of an entrepreneur and investor. He received his PhD in immunology and molecular genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn (Germany) and holds a Masters in international management of biotechnology from the IE Business School. During his scientific tenure he was actively engaged in R&D in and for institutions including University of Cambridge (UK), Michigan University (USA) and Centro Nacional de Investigaciones Oncológicas (CNIO) and authored publications in peer reviewed journals including Nature and Cancer Cell. As a founder and managing partner of Columbus Venture Partners, he has helped developed numerous biotechnology companies in Europe and the US, serving on the Board of Artax Biopharma, Viralgen Vector Core, Polypeptide Therapeutic Solutions, Bioncotech Therapeutics and Sanifit.

Jean Stéphenne

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

+ More info
x

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

Jean Stéphenne is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix (acquired by Takeda in 2019). Jean was previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees. He currently serves on the Board of various life sciences companies including Vaxxilon (DE), OncoDNA (BE), BoneTherapeutics (BE), CureVac (DE) and Bepharbel (BE) as well as in biotech investments funds Vesalius (BE) and Merieux Investments (FR). For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honored with various titles by the Belgian and British governments.

Nicola Zambon

Nicola Zambon

Investor

+ More info
x

Nicola Zambon

Investor

Nicola Zambon has 23 years of M&A and principal investment experience. He is the founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Prior to founding Cleon, he served as director and partner of the private equity firms Investindustrial and Ergon Capital. Nicola is a board member of 15 companies located in various jurisdictions across Europe.

Dr. René Aerts

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

+ More info
x

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

Dr. René Aerts is the Founder of RA-Consultancy BV and currently serves as Partner at NovioCap BV. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previous held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International. He holds non-executive and Advisory Board positions at AGC Biologics (USA), The Jenner Institute (UK), ImmunoValley (NL), Schothorst Feed Research BV (NL) and Alternative Gene Expression Ltd (ES). Mr. Aerts received a PhD in Bioanalytics and Pharmacochemistry from the Free University of Amsterdam in 1990.

Roberto Barzi

Roberto Barzi

Investor

+ More info
x

Roberto Barzi

Investor

Roberto Barzi is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently serves on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health) and Medinet (UK, clinical services).

Julen Oyarzabal

Julen Oyarzabal

Partner at Columbus Venture

+ More info
x

Julen Oyarzabal

Partner at Columbus Venture

Dr. Julen Oyarzabal has spent more than 20 years working in the drug discovery and biopharmaceutical industry. He started his career as researcher at the University of California San Francisco (UCSF) and later he joined the University of Southampton. In 2001, Dr. Oyarzabal joined Johnson & Johnson Pharmaceutical R&D where he led several projects in the CNS therapeutic area. Five years later, he set up and led the Computational Medicinal Chemistry section at the Spanish National Cancer Research Center (CNIO). In 2010, Dr. Oyarzabal joined the Center for Applied Medical Research (CIMA), at the University of Navarra, to set up the small molecule discovery platform and led the Molecular Therapeutics Program. From 2013 to 2018 he was also director of Translational Sciences leading scouting activities, from the University Hospital and CIMA.

He is co-inventor of more than 25 patents and published more than 100 peer-reviewed scientific articles; he (co-)led publications in prestigious journals such as Nature Comm, Angew Chem, or J Med Chem. In addition, Dr. Oyarzabal is on the Board of Directors for the Academic Drug Discovery Consortium (ADDC) and, from 2012 to 2019, he was member of the European Medicines Agency (EMA). As partner of Columbus Venture Partners, he has served on the Board of Polypeptide Therapeutic Solutions.

Shareholders

Algenex is supported by a strong investor base, that includes institutional investors, venture capital funds, founders and the management team.